

Citations

1. Bradley P. British Herbal Compendium. 1 vol. Bournemouth, UK: British Herbal Medical Association; 1992.
2. Johnson S. Feverfew—a Traditional Herbal Remedy for Migraine and Arthritis. London: Sheldon Press; 1984.
3. Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. *Br Med J (Clin Res Ed)* 1985;291:569-573.
4. Weiss R. Herbal Medicine. Meuss A, Translator. 6th ed. Beaconsfield, UK: Beaconsfield Publishers Ltd; 1988.
5. Bisset N. Wichtl's Herbal Drugs and Phytopharmaceuticals. 2nd ed. Stuttgart: Medpharm GmbH; 1994.
6. Blumenthal M, Busse W, Goldberg A et al. The Complete German Commission E Monographs. Austin, Texas: American Botanical Council: Integrative Medicine Communications; 1998.
7. ESCOP. Tanceti Partheni Herba. ESCOP Monographs: the Scientific Foundation for Herbal Medicinal Products. 2nd ed. Exeter, UK: European Scientific Cooperative on Phytotherapy and Thieme; 2003:492-498.
8. Mills S, Bone K. Principles and Practice of Phytotherapy. Edinburgh: Churchill Livingstone; 2000.
9. McKenna D, Jones K, Hughes K, Humphrey S. Feverfew. *Botanical Medicines*. 2nd ed. Binghamton, NY: Haworth Press; 2002:349-373.
10. Ernst E, Pittler MH. The efficacy and safety of feverfew (*Tanacetum parthenium* L.): an update of a systematic review. *Public Health Nutr* 2000;3:509-514.
11. Pittler M, Ernst E. Feverfew for preventing migraine. *Cochrane Database Syst Rev* 2004;1:CD002286.
12. Awang DVC. Prescribing therapeutic feverfew (*Tanacetum parthenium* (L.) Schultz Bip., syn. *Chrysanthemum parthenium* (L.) Bernh.). *Integr Med* 1998;1:11-13.
13. Rungeler P, Castro V, Mora G et al. Inhibition of transcription factor NF- κ B by sesquiterpene lactones: a proposed molecular mechanism of action*1. *Bioorg Med Chem* 1999;7:2343-2352.
14. Koch E, Klaas CA, Rungeler P et al. Inhibition of inflammatory cytokine production and lymphocyte proliferation by structurally different sesquiterpene lactones correlates with their effect on activation of NF- κ B1. *Biochem Pharmacol* 2001;62:795-801.
15. Kwok BH, Koh B, Ndubuisi MI et al. The anti-inflammatory natural product parthenolide from the medicinal herb feverfew directly binds to and inhibits I κ B kinase. *Chem Biol* 2001;8:759-766.
16. Piela-Smith TH, Liu X. Feverfew extracts and the sesquiterpene lactone parthenolide inhibit intercellular adhesion molecule-1 expression in human synovial fibroblasts. *Cell Immunol* 2001;209:89-96.
17. Fiebich BL, Lieb K, Engels S, Heinrich M. Inhibition of LPS-induced p42/44 MAP kinase activation and iNOS/NO synthesis by parthenolide in rat primary microglial cells. *J Neuroimmunol* 2002;132:18-24.
18. Fukuda K, Hibiya Y, Mutoh M et al. Inhibition by parthenolide of phorbol ester-induced transcriptional activation of inducible nitric oxide synthase gene in a human monocyte cell line THP-1. *Biochem Pharmacol* 2000;60:595-600.
19. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the reperfusion injury salvage kinase (RISK) pathway. *Cardiovasc Res* 2004;61:448-460.
20. Cory AH, Cory JG. Augmentation of apoptosis responses in p53-deficient L1210 cells by compounds directed at blocking NF- κ B activation. *Anticancer Res* 2001;21:3807-3811.
21. Wen J, You KR, Lee SY et al. Oxidative stress-mediated apoptosis: the anticancer effect of the sesquiterpene lactone parthenolide. *J Biol Chem* 2002;277:38954-38964.
22. Heptinstall S, Groenewegen WA, Spangenberg P, Loesche W. Extracts of feverfew may inhibit platelet behaviour via neutralization of sulphhydryl groups. *J Pharm Pharmacol* 1987;39:459-465.
23. Heptinstall S. Feverfew—an ancient remedy for modern times? *J R Soc Med* 1988;81:373-374.
24. Zhang S, Ong C-N, Shen H-M. Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. *Cancer Lett* 2004;208:143-153.
25. Liu F, Morris S, Epps J, Carroll R. Demonstration of an activation regulated NF- κ B/I- κ B α complex in human platelets. *Thromb Res* 2002;106:199-203.
26. Steele AJ, Jones DT, Ganeshaguru K et al. The sesquiterpene lactone parthenolide induces selective apoptosis of B-chronic lymphocytic leukemia cells in vitro. *Leukemia* 2006;20:1073-1079.
27. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. *Am J Health Syst Pharm* 2000;57:1221-1227; quiz 1228-1230.
28. Wagner S, Kratz F, Merfort I. In vitro behaviour of sesquiterpene lactones and sesquiterpene lactone-containing plant preparations in human blood, plasma and human serum albumin solutions. *Planta Med* 2004;70:227-233.
29. Tournier H, Schinella G, de Balsa EM et al. Effect of the chloroform extract of *Tanacetum vulgare* and one of its active principles, parthenolide, on experimental gastric ulcer in rats. *J Pharm Pharmacol* 1999;51:215-219.

Citations and Reference Literature: Feverfew

30. Maria AO, Franchi AM, Wendel GH et al. Gastric cytoprotective activity of dehydroleucodine in rats: role of prostaglandins. *Biol Pharm Bull* 1998;21:335-338.
31. Ianaro A, Ialenti A, Maffia P et al. Role of cyclopentenone prostaglandins in rat carrageenin pleurisy. *FEBS Lett* 2001;508:61-66.
32. DeWeerd C, Bootsma H, Hendricks H. Herbal medicines in migraine prevention. *Phytomedicine* 1996;3:225-230.
33. Boik J. *Natural Compounds in Cancer Therapy*. Princeton, Minn: Oregon Medical Press; 2001.
34. Bharti AC, Aggarwal BB. Nuclear factor-kappa B and cancer: its role in prevention and therapy. *Biochem Pharmacol* 2002;64:883-888.
35. Bharti AC, Aggarwal BB. Chemopreventive agents induce suppression of nuclear factor- κ B leading to chemosensitization. *Ann N Y Acad Sci* 2002;973:392-395.
36. Pahl HL. Activators and target genes of Rel/NF- κ B transcription factors. *Oncogene* 1999;18:6853-6866.
37. Cory AH, Cory JG. Lactacystin, a proteasome inhibitor, potentiates the apoptotic effect of parthenolide, an inhibitor of NF- κ B activation, on drug-resistant mouse leukemia L1210 cells. *Anticancer Res* 2002;22:3805-3809.
38. Sweeney CJ, Mehrotra S, Sadaria MR et al. The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. *Mol Cancer Ther* 2005;4:1004-1012.
39. DeGraffenried LA, Chandrasekar B, Friedrichs WE et al. NF- κ B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. *Ann Oncol* 2004;15:885-890.
40. Yip-Schneider MT, Nakshatri H, Sweeney CJ et al. Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. *Mol Cancer Ther* 2005;4:587-594.
41. Taguchi T, Takao T, Iwasaki Y et al. Suppressive effects of dehydroepiandrosterone and the nuclear factor- κ B inhibitor parthenolide on corticotroph tumor cell growth and function in vitro and in vivo. *J Endocrinol* 2006;188:321-331.
42. Wu C, Chen F, Rushing JW et al. Antiproliferative activities of parthenolide and golden feverfew extract against three human cancer cell lines. *J Med Food* 2006;9:55-61.
43. Makheja AN, Bailey JM. A platelet phospholipase inhibitor from the medicinal herb feverfew (*Tanacetum parthenium*). *Prostaglandins Leukot Med* 1982;8:653-660.
44. Heptinstall S, White A, Williamson L, Mitchell JR. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. *Lancet* 1985;1:1071-1074.
45. Loesche W, Mazurov AV, Voyno-Yasenetskaya TA et al. Feverfew—an antithrombotic drug? *Folia Haematol Int Mag Klin Morphol Blutforsch* 1988;115:181-184.
46. Loesche W, Groenewegen WA, Krause S et al. Effects of an extract of feverfew (*Tanacetum parthenium*) on arachidonic acid metabolism in human blood platelets. *Biomed Biochim Acta* 1988;47:S241-243.
47. Groenewegen WA, Knight DW, Heptinstall S. Compounds extracted from feverfew that have anti-secretory activity contain an alpha-methylene butyrolactone unit. *J Pharm Pharmacol* 1986;38:709-712.
48. Marles RJ, Kaminski J, Arnason JT et al. A bioassay for inhibition of serotonin release from bovine platelets. *J Nat Prod* 1992;55:1044-1056.
49. Heptinstall S, Groenewegen WA, Spangenberg P, Losche W. Inhibition of platelet behaviour by feverfew: a mechanism of action involving sulphhydryl groups. *Folia Haematol Int Mag Klin Morphol Blutforsch* 1988;115:447-449.
50. Till U, Bergmann I, Breddin K et al. Sulphydryl/disulfide-status of blood platelets: a target for pharmacological intervention? *Prog Clin Biol Res* 1989;301:341-345.
51. Groenewegen WA, Heptinstall S. A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in-vitro. *J Pharm Pharmacol* 1990;42:553-557.
52. Venton DL, Kim SO, LeBreton GC. Antiplatelet activity from plants. In: Wagner H, Farnsworth NR, eds. *Economic and Medicinal Plant Research*. 5 vol. London: Academic Press; 1991:323-351.
53. Biggs MJ, Johnson ES, Persaud NP, Ratcliffe DM. Platelet aggregation in patients using feverfew for migraine. *Lancet* 1982;2:776.